Sanofi-GSK Covid-19 Vaccine Trial Passes Phase 2; Phase 3 to Start Soon
By Cecilia Butini
Sanofi SA said Monday that the coronavirus vaccine it is
developing with GlaxoSmithKline PLC has achieved positive results
in a Phase 2 trial, and that a global pivotal Phase 3 study is
expected to start in the coming weeks.
The French pharmaceutical major said the vaccine showed strong
rates of neutralizing antibody responses in all adult age groups
that were part of the trial, reaching levels comparable to those
generated by natural infection.
The upcoming Phase 3 trial is expected to enroll more than
35,000 adults from a broad range of countries, assessing the
efficacy of two vaccine formulations that are set to include the
Wuhan and South African variants.
The shot is expected to be approved in the fourth quarter of
2021, pending Phase 3 outcomes and regulatory reviews.
Write to Cecilia Butini at email@example.com
(END) Dow Jones Newswires
May 17, 2021 02:05 ET (06:05 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.